The increased TXLNA expression group had favourable OS in PAAD patients with lymph nodes (p=0.0284; HR: 0.5773; 95% CI: 0.3531–0.9437; Figure 3(c)), but not in PAAD patients with no-lymph nodes (p=0.9996; Figure 3(d)). This evidence concerns the gene TXLNA and pancreatic adenocarcinoma.